Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis

References

• Grace E, Shaw C, Whelan K, et al. Review article: small intestinal bacterial overgrowth–prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674–688.
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Ghoshal U. Small intestinal bacterial overgrowth and other intestinal disorders. Gastroenterol Clin North Am. 2017;46(1):103–120.
   PubMed Web of Science ®Google Scholar
• Losurdo G, Salvatore D’Abramo F, Indellicati G, et al. The influence of small intestinal bacterial overgrowth in digestive and extra-intestinal disorders. Int J Mol Sci. 2020;21(10):3531.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Gerardi V, Gasbarrini A. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Rev Gastroenterol Hepatol. 2016;10(2):215–227.
   PubMed Web of Science ®Google Scholar
• Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020;159(4):1526–1532.
   PubMed Web of Science ®Google Scholar
• Rao SSC, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019;10(10):e00078.
   PubMed Web of Science ®Google Scholar
• Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–784.
   PubMed Web of Science ®Google Scholar
• Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–2990.
   PubMed Web of Science ®Google Scholar
• Adike A, DiBaise JK. Small intestinal bacterial overgrowth: nutritional implications, diagnosis, and management. Gastroenterol Clin North Am. 2018;47(1):193–208.
   PubMed Web of Science ®Google Scholar
• Kogawa AC, Salgado HRN. Status of rifaximin: a review of characteristics, uses and analytical methods. Crit Rev Anal Chem. 2018;48(6):459–466.
   PubMed Web of Science ®Google Scholar
• Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller’s diarrhoea. Drugs. 2005;65(12):1697–1713.
   PubMed Web of Science ®Google Scholar
• Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 2016;22(29):6638–6651.
   PubMed Web of Science ®Google Scholar
• Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14(2):51–56.
   PubMedGoogle Scholar
• Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010;26(1):17–25.
   PubMed Web of Science ®Google Scholar
• Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604–616.
   PubMed Web of Science ®Google Scholar
• Li Y, Hong G, Yang M, et al. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacol Res. 2020;159(104936):104936.
   PubMedGoogle Scholar
• Polkowska-Pruszynska B, Gerkowicz A, Rawicz-Pruszynski K, et al. The role of fecal calprotectin in patients with systemic sclerosis and small intestinal bacterial overgrowth (SIBO). Diagnostics. 2020;10(8):587.
   Web of Science ®Google Scholar
• Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25(7):781–786.
   PubMed Web of Science ®Google Scholar
• Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin. 1999;15(1):47–52.
   PubMed Web of Science ®Google Scholar
• Tuteja AK, Talley NJ, Stoddard GJ, et al. Double-blind placebo-controlled study of rifaximin and lactulose hydrogen breath test in gulf war veterans with irritable bowel syndrome. Digest Dis Sci. 2019;64(3):838–845
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feng Y, Cao B, et al. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis. Int J Clin Exp Med. 2015;8(2):2954–2957.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Tian Z, Luo M, et al. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2020;20(1):187.
   PubMed Web of Science ®Google Scholar
• Shah SC, Day LW, Somsouk M, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925–934.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Tana P, Mengoli C, et al. Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. Intern Emerg Med. 2011;6(5):403–11.
   PubMed Web of Science ®Google Scholar
• Furnari M, Parodi A, Gemignani L, et al. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2010;32(8):1000–1006.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14(5):551–556.
   PubMed Web of Science ®Google Scholar
• Abid S, Kamran M, Abid A, et al. Minimal hepatic encephalopathy: effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes. Sci Rep. 2020;10(1):10079.
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. MOV DISORD. 2013;28(9):1241–1249.
   PubMed Web of Science ®Google Scholar
• Gravina A, Federico A, Ruocco E, et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United Eur Gastroenterol J. 2015;3(1):17–24.
   PubMed Web of Science ®Google Scholar
• Chojnacki C, Konrad P, Blonska A, et al. Usefulness of the hydrogen breath test in patients with functional dyspepsia. Przeglad Gastroenterol. 2020;15(4):338–342.
   PubMed Web of Science ®Google Scholar
• Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res. 1988;16(4):312–316.
   PubMed Web of Science ®Google Scholar
• Enko D, Halwachs-Baumann G, Stolba R, et al. Refining small intestinal bacterial overgrowth diagnosis by means of carbohydrate specificity: a proof-of-concept study. Therap Adv Gastroenterol. 2016;9(3):265–272.
   PubMed Web of Science ®Google Scholar
• Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016–6021.
   PubMed Web of Science ®Google Scholar
• Konrad P, Chojnacki J, Gasiorowska A, et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Przeglad Gastroenterol. 2018;13(3):213–217.
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Bilotta AL, Gabrielli M, et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metabol. 2007;92(11):4180–4184.
   PubMed Web of Science ®Google Scholar
• Majewski M, Reddymasu SC, Sostarich S, et al. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007;333(5):266–270.
   PubMed Web of Science ®Google Scholar
• Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 2012;36(11–12):1084–1093.
   PubMed Web of Science ®Google Scholar
• Biancone L, Vernia P, Agostini D, et al. Effect of rifaximin on intestinal bacterial overgrowth in Crohn’s disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin. 2000;16(1):14–20.
   PubMed Web of Science ®Google Scholar
• Boltin D, Perets TT, Shporn E, et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob. 2014;13(49). doi:https://doi.org/10.1186/s12941-014-0049-x
   Google Scholar
• Chang MS, Minaya MT, Cheng J, et al. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Digest Dis Sci. 2011;56(10):2939–2946
   PubMed Web of Science ®Google Scholar
• Furnari M, De Alessandri A, Cresta F, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019;54(3):261–270.
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22(1):31–35.
   PubMed Web of Science ®Google Scholar
• Gabrielli M, D’Angelo G, Di Rienzo T, et al. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):30–35.
   PubMed Web of Science ®Google Scholar
• Losurdo G, Leandro G, Ierardi E, et al. Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: a Systematic Review With Meta-analysis. J Neurogastroenterol Motil. 2020;26(1):16–28.
   PubMed Web of Science ®Google Scholar
• DiBaise JK, Crowell MD, Driver-Dunckley E, et al. Weight Loss in Parkinson’s Disease: no Evidence for Role of Small Intestinal Bacterial Overgrowth. J Parkinsons Dis. 2018;8(4):571–581.
   PubMedGoogle Scholar
• Campanati A, Gesuita R, Giannoni M, et al. Role of small intestinal bacterial overgrowth and Helicobacter pylori infection in chronic spontaneous urticaria: a prospective analysis. Acta Derm Venereol. 2013;93(2):161–164.
   PubMed Web of Science ®Google Scholar